ReP USP - Resultado da busca

Filtros : "Indexado no Global Health" "ANTINEOPLÁSICOS" "Feldman, Tatyana" Limpar

Filtros

Artigo de periodico
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial (2017)
Prince, H. Miles; Kim, Youn H.; Horwitz, Steven M.; Dummer, Reinhard; Scarisbrick, Julia; Quaglino, Pietro; Zinzani, Pier Luigi; Wolter, Pascal; Sanches, Jose A.; Ortiz-Romero, Pablo L.; Akilov, Oleg E.; Geskin, Larisa; Trotman, Judith; Taylor, Kerry; Dalle, Stephane; Weichenthal, Michael; Walewski, Jan; Fisher, David; Dréno, Brigitte; Stadler, Rudolf; Feldman, Tatyana; MKuzel, Timothy; Wang, Yinghui; Palanca-Wessels, Maria Corinna; Zagadailov, Erin; Trepicchio, William L; Zhang, Wenwen; Lin, Hui-Min; Liu, Yi; Huebner, Dirk; Little, Meredith; Whittaker, Sean; Duvic, Madeleine
Source: Lancet. Unidade: FM
Subjects: LINFOMA, ESTRATÉGIAS TERAPÊUTICAS, ANTINEOPLÁSICOS, MANIFESTAÇÕES CUTÂNEAS, PROGNÓSTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PRINCE, H. Miles et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet, v. 390, n. 10094, p. 555-566, 2017Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(17)31266-7. Acesso em: 10 nov. 2024.
APA
Prince, H. M., Kim, Y. H., Horwitz, S. M., Dummer, R., Scarisbrick, J., Quaglino, P., et al. (2017). Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet, 390( 10094), 555-566. doi:10.1016/S0140-6736(17)31266-7
NLM
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, MKuzel T, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin H-M, Liu Y, Huebner D, Little M, Whittaker S, Duvic M. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial [Internet]. Lancet. 2017 ; 390( 10094): 555-566.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1016/S0140-6736(17)31266-7
Vancouver
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, MKuzel T, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin H-M, Liu Y, Huebner D, Little M, Whittaker S, Duvic M. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial [Internet]. Lancet. 2017 ; 390( 10094): 555-566.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1016/S0140-6736(17)31266-7

Digital Library of Intellectual Production of Universidade de São Paulo 2012 - 2024